J Biol Chem, Vol. 274, Issue 46, 33064-33071, November 12, 1999
Functional Analysis of a Single Chain Chimeric
/
-Granulocyte-Macrophage Colony-stimulating Factor Receptor
IMPORTANCE OF A GLUTAMATE RESIDUE IN THE TRANSMEMBRANE
REGION*
Sabine
Kafert,
Susanne
Luther,
Inga
Böll,
Katharina
Wagner,
Arnold
Ganser, and
Matthias
Eder
From the Department of Hematology and Oncology, Hannover Medical
School, D-30625 Hannover, Germany
 |
ABSTRACT |
To analyze the function of each subunit of the
receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF),
GMR, we previously generated a single-chain chimeric receptor by fusion of the extracellular and transmembrane domain from the
-subunit (
-GMR) to the intracellular part of the
-subunit (
-GMR)
introducing an additional glutamate residue at the fusion site
(
/
-GMR). We demonstrated the capacity of
/
-GMR to bind
GM-CSF with low affinity and to induce GM-CSF-dependent
activation of tyrosine kinase activity and proliferation in transfected
Ba/F3 cells. To further compare the functions of wild type and chimeric
receptors, we now report that this
/
-GMR is sufficient to mediate
morphological changes, expression of
4- and
1-integrin receptor subunits, and serine-phosphorylation
of Akt kinase. To analyze the function of the glutamate residue at the
fusion region of
/
-GMR various point mutants changing this amino
acid and its position were expressed in Ba/F3 cells. None of these
mutants was capable of supporting GM-CSF-dependent
proliferation; however, when
-GMR was coexpressed, GM-CSF mediated
short and long term proliferation. Interestingly, some mutants but not
/
-GMR can induce proliferation in the presence of an anti-
-GMR
antibody. These data demonstrate the significance of a glutamate
residue in the transmembrane region of
/
-GMR for ligand-induced
receptor activation.
 |
INTRODUCTION |
Granulocyte-macrophage colony-stimulating factor
(GM-CSF)1 mediates
proliferation, survival, differentiation, and functional activities in
myeloid cells (1, 2). GM-CSF binds to the GM-CSF receptor (GMR),
consisting of a low affinity binding
-subunit (
-GMR) und a high
affinity converting
-subunit essential for signal transduction and
shared with the receptors for IL-3 and IL-5 (common
;
c;
-GMR) (3-6). Both receptor chains belong to the
cytokine receptor family characterized by common sequence and
structural motifs such as the WSXWS motif in the
extracellular domain close to the cell membrane (7).
The initial events of ligand-induced cytokine receptor activation are
not completely understood. For single chain receptors such as EpoR or
granulocyte colony-stimulating factor receptor, ligand-induced receptor
dimerization is believed to mediate activation of receptor associated
tyrosine kinases of the JAK family (8, 9). However, recent studies on
the EpoR demonstrate a ligand-induced conformational change in
preformed receptor complexes and suggest that dimerization or
oligomerization may be necessary but not sufficient for the initiation
of intracellular signal transduction (10). Both models for receptor
activation, ligand-induced assembly of receptor chains and
ligand-dependent conformational changes in preformed
receptor complexes, may also be involved in the activation of
heteromeric cytokine receptors such as GMR. Indeed, we have shown the
GM-CSF-dependent coimmunoprecipitation of human
-GMR and
-GMR in transfected NIH3T3 cells (11), and Woodcock et al. (12) demonstrated the existence of both preformed and
GM-CSF-inducible GMR complexes with different ratios of each in
different hematopoietic cells.
The initial event in intracellular signaling of cytokine receptors is
believed to be the transphosphorylation and activation of members of
the JAK tyrosine kinase family. The kinases may constitutively
associate with receptor chains as demonstrated for the interaction of
JAK2 and
-GMR (13) or EpoR (14), and the kinases may be brought into
a steric conformation enabling activation upon ligand-receptor
interaction (10). Alternatively, JAKs may be recruited into
ligand-activated receptor complexes (15), for example by ligand-induced
unfolding of motifs in receptor subunits involved in receptor-kinase
interaction. To analyze the contribution of individual receptor domains
of human
-GMR and
-GMR, we previously cloned a chimeric
/
-GMR by fusion of the extracellular and transmembrane sequence
of
-GMR to the intracellular part of
-GMR that we found capable
of GM-CSF binding with low affinity, receptor internalization,
induction of tyrosine kinase activity, and short and long term
proliferation of transfected Ba/F3 cells in the absence of wild type
human
-GMR and
-GMR (11). This
/
-GMR contains an additional
glutamate residue at the fusion region introduced for cloning purposes.
In contrast to this construct, several groups reported on slightly
different chimeric
/
-GMR and IL-5R
/
-GMR constructs that
were only functional as high affinity receptors in the presence of
-GMR (16, 17). It was concluded from these studies that the
cytoplasmic domain of
-GMR, although indispensable for the function
of the wild type GMR (18-20), does not harbor nonredundant and
necessary sequences for the functions analyzed so far in transfected
cells. However, some unique signaling capacities of
-GMR have been
reported (21, 22), and ligand-dependent signaling even in
the absence of
-GMR such as induction of glucose uptake has also
been linked to
-GMR (23).
To further compare the functions mediated by the wild type GMR and the
chimeric
/
-GMR and to identify potential defects due to the lack
of
-GMR sequences, we now extend the characterization of
/
-GMR
and demonstrate its capacity to signal for reorganization of the
cellular cytoskeleton and morphological changes, for surface expression
of
4- and
1-integrins, and for serine
phosphorylation of Akt protein kinase at Ser-473 in a
GM-CSF-dependent manner. Moreover, we demonstrate the
essential function of a glutamate residue at a specific position at the
transition of the transmembrane to the cytoplasmic region for
ligand-induced receptor function, providing new insights into initial
events of GMR activation.
 |
MATERIALS AND METHODS |
Reagents--
Restriction enzymes, DNA-modifying enzymes, and
DNA molecular weight markers were purchased from MBI Fermentas
(Vilnius, Lithuania) or New England Biolabs (Schwalbach, Germany). All
PCR primers were synthesized by MWG-BIOTECH (Ebersberg, Germany). Fine
chemicals were purchased from Sigma (Deisenhofen, Germany) and were of
analytical or molecular biology grade. Agarose for gel electrophoresis
was from Life Technologies, Inc.
Plasmids and Cloning of Human
/
-GMR Mutants--
Cloning
of the chimeric receptor
/
-GMR introducing a glutamate residue
has been described (11). Nucleotide positions of the
-GMR cDNA
insert are given according to Hayashida et al. (3).
Site-directed mutagenesis was performed using the QuickChange Mutagenesis Kit (Stratagene) and oligonucleotides encoding the desired
mutant sequences as recommended by the manufacturer (see Table II).
Successful cloning was confirmed by restriction analysis and by
sequencing of the mutated region. All constructs are cloned into
pcDNA3 (InVitrogen).
Transfection of Ba/F3 Cells--
The murine cell line Ba/F3 was
cultured in RPMI medium supplemented with glutamic acid, antibiotics,
5% fetal calf serum (Biochrome), and 10% WEHI-conditioned medium for
the supply of murine IL (mIL)-3. In initial experiments, recombinant
mIL-3 (10 ng/ml; Sigma) was found to be as effective as 10% WEHI-CM to
induce proliferation, morphological changes, and Akt phosphorylation.
For transfection, 1-2 × 106 cells were washed twice
in RPMI 1640 without any supplements and electroporated at 350 V and
950 microfarads in 800 µl of serum-free medium in the presence of 20 µg of expression vector encoding the respective GMR constructs,
purified by phenol/chloroform extraction. After 2 days, the cells were
washed, split in half, and selected under two conditions in order to
test the capacity of the transfected receptor variant to support
GM-CSF-dependent proliferation: 1) in the presence of 20 ng/ml recombinant hGM-CSF but without mIL-3 or 2) in the presence of
mIL-3 and the antibiotic G418 (Sigma) at a concentration of 1 mg/ml.
RT-PCR Analysis--
For analysis of mRNA expression of
/
-GMR variants, total cellular RNA was prepared from transfected
cells using TRIZOLTM reagent (Life Technologies) according to the
instructions of the manufacturer. cDNA was transcribed from 2.5 µg of total cellular RNA in a 50-µl reaction mix containing 100 units of Moloney murine leukemia virus reverse transcriptase (RT) in
the appropriate buffer conditions (Stratagene), 40 units of RNase
inhibitor (RNase Block, Stratagene), 1 µg of oligo(dT) (Amersham
Pharmacia Biotech), 10 mM dithiothreitol, and nucleotides
at a concentration of 1 mM each (Roche Molecular
Biochemicals). Using the primers 5'-GGAGGACAGGACCAAAAGG (sense) and
5'-CCCCAGGCTTGTTGACC (antisense), a
-GMR fragment corresponding to
nucleotides 2078-2711 was amplified from 10 µl of the RT reaction in
a volume of 50 µl containing 50 pmol of both sense and antisense
primer, 4 µl of 10× PCR buffer, including 15 mM
MgCl2, and 2.5 units of Taq polymerase (Sigma)
by 40 cycles of denaturation (95 °C), annealing (55 °C), and
extension (73 °C). As a control, tubulin was amplified under the
same conditions using the primers
5'-TTCCCTGCCCAGCT(G/C)AANGCNGACCTNCGCAAG (sense) and
5'-CATGCCCTCGCCNGTGTACCAGTGNANGAAGGC (antisense) (where N represents any nucleotide).
FACS Analysis--
Surface expression of the
/
-GMR
variants was analyzed using an antibody against an extracellular
epitope of the human
-GMR subunit (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA; GM-CSR
S-20; 2 µg/106 cells). The
cells were stained with a fluorescein isothiocyanate-labeled rabbit
anti-mouse antibody (Dianova). For analysis of integrin expression,
specific antibodies and isotype controls were obtained from Pharmingen
(integrin
4/mouse CD49d, 01270D; isotype control, 34491A; integrin
1/mouse CD29, 09351D; isotype control,
34481A). The cells were stained with an R-phycoerythrin-conjugated
F(ab')2 goat anti-rat IgG Fragment (1623/112-116-143;
Dianova). All antibodies were used at 10 µg/ml in phosphate-buffered saline.
Immunoblotting--
Transfected Ba/F3 cells were starved
overnight for mIL-3 and hGM-CSF, respectively, and restimulated with
either hGM-CSF or mIL-3 for 5 min. Cellular lysates were prepared as
described (11). Briefly, stimulation was stopped by the addition of ice
cold phosphate-buffered saline, the cells were collected by
centrifugation at 500 g, and the pellets were suspended in lysis
buffer. After 15-25 min on ice, the lysates were cleared by
centrifugation at 4 °C, 12,000 × g for 15 min, and
the supernatants were stored in aliquots at
80 °C or in Laemmli
buffer at
20 °C. The protein concentrations were quantitated using
Bio-Rad reagents, and equal amounts of cellular proteins were separated
by SDS-polyacrylamide gel electrophoresis. Akt phosphorylation was
analyzed by immunoblotting with an antibody recognizing Akt
phosphorylated at Ser-473 (PhosphoPlus® Akt(Ser473)
Antibody Kit, New England Biolabs). As a loading control, the same
lysates were processed simultaneously and probed with a
phosphorylation-independent anti-Akt antibody supplied with the kit.
Binding of 125I-Labeled GM-CSF--
Transfected
Ba/F3 cells were studied for GM-CSF binding as described (11). Briefly,
7.5 × 105 cells were incubated for 60 min on ice with
125I-labeled GM-CSF (NEN Life Science Products) at
different concentrations between 0.04 and 6.42 nM in the
presence or absence of unlabeled GM-CSF (1 µM). However,
in repeated experiments, saturation could not be reached under the
conditions tested even if undiluted 125I-GM-CSF was added
to the cell samples. After incubation, the samples were centrifuged,
resuspended, and layered over a cushion of 0.7 ml of fetal calf serum.
After centrifugation, the supernatant was discarded, and the
radioactivity was measured in a Berthold MAG 315
-counter.
Untransformed specific binding data were analyzed by Scatchard plot
assuming a single class of binding sites. KD and
Bmax represent the equilibrium dissociation
constant and the density of the binding sites per cell, respectively.
Proliferation Assay--
GM-CSF-dependent
proliferation of Ba/F3 cells was assayed using the
CyQUANT® Cell Proliferation Assay Kit (Molecular Probes,
Inc., Eugene, OR) according to the instructions of the manufacturer.
Briefly, the cells were seeded in 96-well tissue culture plates at a
density of 105 cells per 200 µl in the absence or
presence of hGM-CSF ranging from 1 pg/ml to 1 µg/ml. After 48-72 h,
the cells were harvested by centrifugation, lysed in the buffer
provided with the kit, and stained with the CyQUANT GR dye for 5 min at
room temperature. Fluorescence was quantitated using an enzyme-linked
immunosorbent assay reader (540 nm).
Prediction of Protein Structure--
Predictions of protein
structure were done using the SEMAP
program,2 utilizing the
parameters of Chou and Fasman (24) and Kyte and Doolittle (25) to
predict averaged secondary structure and hydrophobicity in protein
chains, respectively. For the analysis discussed in this paper, a range
of 4 amino acids was used for the averaged prediction.
 |
RESULTS |
/
-GMR Mediates GM-CSF-dependent Changes in the
Cell Morphology--
In order to compare the functional capacities of
the wild type
+
GMR and the chimeric
/
-GMR and to
identify potential defects due to the lack of
-GMR sequences in the
chimeric receptor, we expressed
-GMR together with
-GMR or
/
-GMR alone in the murine IL-3-dependent cell line
Ba/F3. This cell line expresses the murine IL-3 receptor including the
murine common
-chain but does not respond to murine GM-CSF, mIL-5,
or hGM-CSF. Since human receptors for GM-CSF lack cross-reactivity to
murine cytokines, their function can easily be analyzed after
expression in these cells.
Growth factor-induced changes in cell morphology of Ba/F3 cells were
studied by phase-contrast microscopy every 10 min after starvation and
restimulation with mIL-3 and hGM-CSF, respectively. When untransfected,
wild type
+
-GMR- or chimeric
/
-GMR-expressing Ba/F3 cells
were starved for growth factor overnight, all cells in culture were of
a circular shape the next morning. However, 1 h after
restimulation with mIL-3 or hGM-CSF for GMR-expressing cells, symmetric
and asymmetric cylindric cells with motile protrusions and cells of
unregular, biconcave shape were present, which increased in frequency
to up to 50% within 6 h. In wild type
+
-GMR- and in
chimeric
/
-GMR-expressing cells, the effects of GM-CSF were more
modest as compared with mIL-3 in some experiments. The mIL-3- or
hGM-CSF-induced changes in cell morphology could be delayed by
preincubation with the PI-3K inhibitor wortmannin and severely
diminished or completely blocked by the repeated addition of wortmannin
every 60 min without any loss of cell viability (Table
I (top) and data not shown).
View this table:
[in this window]
[in a new window]
|
Table I
Morphological changes of Ba/F3 cells in response to growth factor
Untransfected Ba/F3 cells (top) and transfected Ba/F3 cells (bottom)
were starved overnight and restimulated the next morning with either
10% WEHI supernatant as a source of murine IL-3 (mIL-3) or with
hGM-CSF (GM; 20 ng/ml). Wortmannin (Wo; 20 nM final
concentration) was given 45 min prior to growth factor stimulation and
at the time of stimulation alone (single dose) or every hour (repeated
treatment; rep.). Thereafter, each sample was evaluated by
phase-contrast microscopy after 1, 2, 3, 4, and 5 h for the
presence of cells with marked morphological alterations as indicated:
o, 0%; (+), >0-5%; +, 5-10%; ++, 10-25%; +++, 25-40%; ++++,
>40% of the cells deviating from round shape. One representative
experiment is documented.
|
|
GM-CSF-dependent Up-regulation of
4- and
1-Integrin Expression in
/
-GMR-expressing Ba/F3
Cells--
In previous studies, the ability of Ba/F3 cells to adhere
to fibronectin has been used to monitor functional activity of these cells (26). Since we noted adhesion of
/
-GMR-expressing Ba/F3 cells to fibronectin, but not to collagen or gelatin, after stimulation with mIL-3 or hGM-CSF in a Ca2+-dependent
manner in preliminary experiments, the surface expression of murine
4- and
1-integrin subunits was studied by
FACS analysis. When untransfected Ba/F3 cells were starved and
restimulated with mIL-3, a slight but reproducible up-regulation of
4- and
1-integrin subunits at the cell
surface was first detectable after 1 h and increased further
during a time course of 3-6 h (data not shown). Similarly, in
/
-GMR-expressing Ba/F3 cells stimulated for 4 h with either
mIL-3 or hGM-CSF, a small but reproducible up-regulation of
4- and more distinct
1-integrin
expression was detected in several independent clones of
/
-GMR-transfected cells (Fig. 1).
hGM-CSF induced up-regulation of integrin subunits to the same extent
as mIL-3.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Surface expression of integrin subunits
4 and
1 in Ba/F3 cells. Ba/F3 cells
transfected with / -GMR were starved overnight for growth factor
and stimulated the next morning with mIL-3 or hGM-CSF (hGM) for 4 h. Surface expression of integrin subunits 4 and
1 was detected by FACS analysis and is shown as absolute
number of positive cells graphed versus fluorescence
intensity. Increased surface expression after growth factor stimulation
is shown in comparison with the unstimulated controls for two
representative clones transfected with / -GMR. Negative controls
with the second step antibody alone and with isotype control antibodies
were identical in any conditions (not shown).
|
|
IL-3- and GM-CSF-induced Serine Phosphorylation of Akt Protein
Kinase--
The phosphorylation of the serine/threonine kinase Akt at
the regulatory position, Ser-473, was analyzed in untransfected, wild
type
-GMR-, wild type
+
-GMR-, or chimeric
/
-GMR-expressing Ba/F3 cells. Cells were starved overnight and
restimulated the next morning with either mIL-3 or hGM-CSF. Akt
phosphorylation was analyzed in cellular lysates by immunoblotting with
a monoclonal antibody specific for Akt phosphorylated at Ser-473. Akt
phosphorylated at Ser-473 is undetectable in untransfected Ba/F3 cells
after overnight starvation but is clearly found after 5 min of
stimulation with mIL-3 (Fig.
2A). As expected,
untransfected cells do not respond to hGM-CSF. In contrast, both wild
type
+
-GMR- and
/
-GMR-transfected Ba/F3 cells display Akt
phosphorylation at Ser-473 in response to both mIL-3 and hGM-CSF. The
extent of Akt phosphorylation seems to be lower after stimulation with
hGM-CSF as compared with mIL-3 in these experiments. When the cells
were pretreated with wortmannin, the level of Akt phosphorylation was considerably lowered (Fig. 2B). Notably, in Ba/F3
transfectants expressing
-GMR alone, GM-CSF did not induce
detectable phosphorylation of Akt at Ser-473.

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 2.
Immunoblotting of Akt phosphorylated at
Ser-473. Ba/F3 cells transfected with / -GMR (shown as
/ -GMR-Glu), -GMR alone, or + -GMR as well as
the parental cell line were starved overnight for growth factor and
stimulated the next morning with mIL-3 or hGM-CSF for 5 min. Total
cellular lysates were prepared and analyzed after SDS-polyacrylamide
gel electrophoresis and Western blotting with an antibody against the
phosphorylated epitope including Ser-473 of Akt or against a
phosphorylation-independent Akt epitope (A). Where
indicated, the cells were pretreated with the PI-3K inhibitor
wortmannin (Wo) 45 min prior to growth factor stimulation
(20 nM in Me2SO; Me2SO alone had no
effect) (B).
|
|
Cloning and Expression of
/
-GMR Point Mutants--
In
contrast to chimeric constructs composed of sequences from
-GMR and
-GMR reported by others (16),
/
-GMR is capable of
GM-CSF-dependent signal transduction as a low affinity GMR in the absence of
-GMR. We therefore analyzed the function of the
additional glutamate residue introduced at the fusion region of the
transmembrane
-GMR sequence to the cytoplasmic sequence of
-GMR
by generation of the following point mutations using site-directed
mutagenesis (Table II): deletion of the
additional glutamate residue (
/
-GMR-
Glu); replacement with
glutamine (
/
-GMR-Gln) or glycine (
/
-GMR-Gly), respectively;
and positioning of the glutamate residue by 1 (
/
-GMR-Glu(
1)) or
14 amino acids (
/
-GMR-Glu(
14)) to the N terminus, respectively.
/
-GMR-Glu(
14) was generated in analogy to a transforming
-GMR mutant V449E (27).
/
-GMR and all variants were
transfected into Ba/F3 cells, and clones were selected either in
hGM-CSF or with G418 in the presence of mIL-3. Whereas Ba/F3 cells
transfected with the
/
-GMR cDNA could be grown in the
presence of hGM-CSF as reported earlier (11), only drug-resistant and
mIL-3-dependent clones could be selected for all
/
-GMR mutants (up to three independent experiments per mutant;
data not shown). Expression of the receptor cDNA was confirmed on
the mRNA level by RT-PCR, and surface expression was studied by
FACS analysis (Fig. 3). While
/
-GMR
and
/
-GMR-
Glu were expressed at comparable levels, surface
expression of
/
-GMR-Gln,
/
-GMR-Gly, and
/
-GMR-Glu(
14) was more modest. Surface expression of
/
-GMR-Glu(
1) could not be detected by FACS analysis in eight independent RT-PCR positive clones. Nevertheless, the variant turned
out to be functionally expressed as confirmed by cotransfection of wild
type
-GMR (see below). To analyze GM-CSF binding by
/
-GMR mutants with comparable receptor expression as determined by FACS analysis, the equilibrium binding characteristics of the clones
/
-GMR and of
/
-GMR-
Glu were studied. The estimated
values for KD were 1.5 and 1.2 nM, and
the receptor numbers per cell were 4700 and 2000 for
/
-GMR- and
/
-GMR-
Glu-expressing cells, respectively, as derived from
Scatchard plot analysis. We also performed iterative fitting by least
square regression and obtained comparable values (data not shown).
View this table:
[in this window]
[in a new window]
|
Table II
Sequence comparison of the transmembrane region from GMR subunits and
related molecules
The table indicates the transmembrane domain sequences of the wild type
(wt) GMR subunits and the chimeric single chain variants together with
the neighboring amino acids. The sequence from GMR is in roman type,
GMR is in italic type, and the fusion between GMR and GMR
sequence is marked by an asterisks. The putative transmembrane region
is underlined according to published data (see references in the
table). Amino acids inserted into the wild type sequence are given in
parenthesis (boldface type), and amino acid exchanges are indicated by
an arrow (boldface type).
|
|

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 3.
Surface expression of
/ -GMR variants expressed
in Ba/F3 cells. Stable transfectants generated with the
/ -GMR point mutants described in Table II were stained for
surface expression of the receptor with an antibody against the
extracellular part of human -GMR in comparison with untransfected
Ba/F3 cells. The absolute numbers of positive cells are graphed
versus fluorescence intensity.
|
|
Function of
/
-GMR Point Mutants--
For functional
analysis, two independently derived Ba/F3 clones expressing each of the
/
-GMR mutants were tested for GM-CSF-dependent proliferation in the absence of mIL-3. Except for
/
-GMR
transfectants, Ba/F3 cells expressing any of the
/
-GMR mutants
failed to proliferate in the absence of mIL-3, and all cells died
within 48-72 h in the presence of hGM-CSF. However, when Ba/F3 clones
expressing mutant
/
-GMR constructs were co-transfected with wild
type
-GMR and selected with hGM-CSF, double transfectants were
obtained for every
/
-GMR mutant. Again,
GM-CSF-dependent proliferation was assayed for double
transfected cells. In contrast to the single transfectants, all
double-transfected Ba/F3 cells were capable of signaling for
GM-CSF-dependent proliferation (Fig.
4, A-F), whereas Ba/F3 cells
transfected with
-GMR alone did not grow in the presence of hGM-CSF
(data not shown). In addition, all double transfected clones besides
/
-GMR-Glu(
1)-expressing cells could be grown in hGM-CSF for
several weeks in a factor-dependent manner. In contrast,
/
-GMR-Glu(
1)-expressing cells tended to transform rapidly to
factor-independent growth either in the presence or absence of
-GMR
after culture in mIL-3 or hGM-CSF in some experiments (data not
shown).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 4.
GM-CSF dependent proliferation of transfected
Ba/F3 cells. Ba/F3 cells stably transfected with / -GMR or
the point mutants described in Table II alone ( ) or with -GMR
( ) were tested for GM-CSF-dependent proliferation in
comparison with untransfected Ba/F3 cells ( ). The cells were washed
twice in the absence of growth factor and seeded in the presence of
increasing GM-CSF concentrations in a 96-well cell culture plate. After
48-72 h, the cells were collected, and DNA was quantitated with
CyQUANT dye GR. The data presented in this figure were
generated in three different experiments. In all cases, the
background-corrected maximum fluorescence intensity (100%) was between
63 and 139 relative fluorescence units at 540 nm.
|
|
To address the effect of bridging the single chain chimeric
/
-GMR
mutants,
/
-GMR- and
/
-GMR-
Glu-transfected Ba/F3 cells were seeded without growth factor in the presence of increasing concentrations of an anti-
-GMR antibody (Fig.
5). Interestingly, cross-linking of
/
-GMR-
Glu but not
/
-GMR by an anti-
-GMR antibody was
sufficient to induce cell survival and proliferation in a
dose-dependent manner. Similarly,
/
-GMR-Gln-transfected Ba/F3 cells were also able to grow in the
presence of anti-
-GMR antibody (data not shown).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 5.
Proliferation of transfected Ba/F3 cells in
the presence of a cross-linking anti- -GMR
antibody. Ba/F3 cells expressing / -GMR (A) or
/ -GMR- Glu (B) were washed twice in the absence of
growth factor, and 5 × 104 cells were seeded either
without growth factor (control) or in the presence of 20 ng/ml hGM-CSF,
increasing amounts of anti-human -GMR antibody (S-20; Santa Cruz
Biotechnology), 10 ng/ml mIL-3, or 20 µg/ml anti-human -GMR
antibody (S-16; Santa Cruz Biotechnology), respectively. Viable cells
were counted after 4 days of culture. Untransfected Ba/F3 cells did not
survive with either anti- -GMR or anti- -GMR antibody in the
absence of mIL-3 (not shown).
|
|
Prediction of Secondary Protein Structure--
To further analyze
the role of the glutamate residue close to the transition of the
transmembrane to the cytoplasmic region, we performed prediction of the
hydrophobicity and of the secondary structure of this region for
/
-GMR and each of the
/
-GMR mutants in comparison with the
wild type subunits (Fig. 6 and data not shown). Introduction of either glutamate (
/
-GMR) or glutamine (
/
-GMR-Gln) markedly changes the hydrophobicity as compared with
/
-GMR-
Glu (Fig. 6). As expected, the effect of glycine introduction is more modest, while introduction of glutamate at positions
1 and
14 again enhance the hydrophilicity at the
respective sites (not shown). Interestingly, the analysis suggests a
-sheet rather than
-helical conformation of this part of the
transmembrane domain for both wild type
- and
-GMR as well as the
chimeric variants.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 6.
Protein structure prediction for the
transmembrane region of GMR molecules. SEMAP analysis of the
transmembrane domain sequences, together with the neighboring amino
acids indicated in Table II, was carried out for / -GMR,
/ -GMR- Glu (shown as / -GMR- E),
and / -GMR-Gln. Amino acids are indicated corresponding to Table
II. Hydrophilicity is plotted against amino acid positions. and denote the probability that the respective amino acid supports
-helical or -sheet secondary structures, respectively, in the
specific context. , no predisposition.
|
|
 |
DISCUSSION |
This study explores the functional capacities of a low affinity
single chain chimeric
/
-GMR in the absence of intracellular
-GMR sequences when stably expressed in Ba/F3 cells. We have previously shown that the chimeric
/
-GMR is sufficient for
GM-CSF-dependent short and long term proliferation of Ba/F3
and 32D cells (Ref. 11 and data not shown) and of inducing
GM-CSF-dependent tyrosine phosphorylation of cellular
substrates. We show here that
/
-GMR-expressing Ba/F3 cells also
display GM-CSF-dependent changes in cell morphology, surface expression of integrin subunits, and serine phosphorylation of
the serine/threonine kinase Akt (or protein kinase B), implicated in
antiapoptotic signaling (28, 29).
Cytoskeletal function and integrin expression are regulated by IL-3 or
GM-CSF in wild type GMR and in
/
-GMR-expressing Ba/F3 cells. Both
functions are involved in regulating the interaction of hematopoietic
cells with the microenvironment, and defects of both cytoskeletal
functions and adhesion are found in Bcr-Abl-expressing cells (30, 31).
The biochemical events mediating the effects of IL-3 or GM-CSF on cell
morphology and
4- and
1-integrin
expression are currently not exactly characterized, but they are
likely to involve small GTPases of the Rac/Rho/Cdc42 family
for mediating membrane ruffling, formation of actin stress fibers,
lamellipodia, and increased cell motility (32). We show here that IL-3-
and GM-CSF-induced changes in cell morphology of Ba/F3 cells require activity of PI-3K and do not necessarily require sequences encoded by
the cytoplasmic region of
-GMR.
The serine/threonine kinase Akt is linked to the apoptotic cell
machinery through at least one of its substrates, the proapoptotic BCL-2 family member BAD, which can be phosphorylated at Ser-136 by Akt
(29). BAD interacts with 14-3-3 protein isoforms in a phopsphoserine-dependent manner that appears to prevent the
proapoptotic association of BAD with BCL-2 or BCL-XL (29).
In addition, Akt has been shown to become phosphorylated and activated
by IL-3 in hematopoietic cells (33). Both IL-3-induced phosphorylation and activation of Akt depend on PI-3K activity, and the pleckstrin homology domain of Akt is believed to mediate recruitment of Akt to the
cell membrane by interaction with phosphatidylinositol products
resulting from PI-3K activity. Although Akt has been demonstrated to be
necessary and sufficient for suppression of apoptotic death of neuronal
cells in culture (29, 34), its function on
cytokine-dependent survival of hematopoietic cells is
currently not known. We show here that both IL-3 and GM-CSF induce
phosphorylation of Akt at Ser-473 in a PI-3K-dependent manner. In addition, whereas the cytoplasmic domain of
-GMR is not
required, the cytoplasmic domain of
-GMR is essential for serine
phosphorylation of Akt. Interestingly, Ba/F3 cells expressing wild type
-GMR do not show detectable phosphorylation of Akt after stimulation
with GM-CSF but can be grown with high concentrations of GM-CSF for
several weeks. These data suggest that phosphorylation of Akt may not
be essential for survival of hematopoietic cells under the conditions tested.
GM-CSF-dependent effects on cell morphology, integrin
surface expression, and Akt phosphorylation in
/
-GMR-transfected
Ba/F3 cells occur in the absence of cytoplasmic
-GMR sequences.
Therefore, with respect to all of these functions and in addition to
survival, proliferation, receptor internalization, and tyrosine
phosphorylation (11), the intracellular
-chain can be replaced by
sequences of
-GMR in this specific
/
-GMR. Interestingly, human
-GMR has been described to exist as a constitutively preformed
homodimer both in vivo (35) and in
vitro.3 Since the
intracellular domain of
-GMR cannot be deleted in the wild type GMR
without loss of receptor function (18-20), our data suggest a
potential role of intracellular
-GMR sequences in the initial
positioning or in inducing an appropriate conformational change of
-GMR chains leading to activation of JAK2 through the wild type GMR.
Additionally, sequences from
-GMR may also be involved in
terminating GMR signaling.
Point mutations in the transmembrane region of
/
-GMR were found
to affect surface expression, GM-CSF binding, and functions such as
mitogenic signaling, cytoskeletal changes, and phosphorylation of Akt
in Ba/F3 cells expressing the respective GMR chimeras. Whereas
deletion of the glutamate residue slightly enhances surface expression
as compared with
/
-GMR, replacement by glycine or glutamine at
identical positions as well as positioning of the glutamate residue 14 amino acids to the N terminus decreases expression of the respective
receptor. Interestingly, surface expression of
/
-GMR-Glu(
1) was
not detectable at all by FACS analysis, but
GM-CSF-dependent signaling upon coexpression of
-GMR
implies its presence at the cell surface. We are currently
investigating the mechanism of the reduced surface expression of the
/
-GMR-Glu(
1) variant in comparison with the other receptor chimeras.
The mechanism involved in activation of the single chain
/
-GMR,
i.e. GM-CSF-induced homo-oligomerization or association with
endogenous signaling molecules such as AIC2B or molecules that
substitute for the function of
-GMR sequences, are currently not
known. To distinguish between these possibilities, we transfected murine 3T3 fibroblasts with the cDNA encoding
/
-GMR. So far we could not find any biochemical evidence for
GM-CSF-dependent receptor function in several independent
RT-PCR positive clones. However, since we failed to prove surface
expression of
/
-GMR so far, we cannot decide between both
mechanisms of receptor activation in the fibroblast model (data not
shown). In addition, receptor cross-linking by an anti-
-GMR antibody
had no proliferative effect in
/
-GMR transfected Ba/F3 cells. In
contrast,
/
-GMR-
Glu- and
/
-GMR-Gln-transfected
Ba/F3 cells, which cannot proliferate in response to hGM-CSF, were able
to survive and proliferate in the presence of the tested anti-
-GMR
antibody in a dose-dependent manner. Therefore, the
glutamate residue in the single chain chimeric
/
-GMR is essential
for ligand-dependent receptor function but precludes
activation by the cross-linking antibody used in this study. Since the
reverse is true for the variants
/
-GMR-
Glu and
/
-GMR-Gln, ligand- and antibody-dependent receptor
activation seem to be mutually exclusive.
As shown by the present study, a glutamate residue at a unique position
in the transmembrane region at the transition to the cytoplasm is
necessary for GM-CSF-dependent signaling of
/
-GMR. Prediction of secondary protein structure cannot explain the unique features of the glutamate residue, since there was no significant difference between the functional
/
-GMR and the nonfunctional
/
-GMR-Gln. These data suggest that the negative charge introduced by the glutamate residue in
/
-GMR as opposed to glutamine is essential for ligand-dependent receptor function of
/
-GMR. Interestingly, there are several observations describing a
specific role of glutamate residues within the transmembrane region for
constitutive receptor activation. First, mutational screens for
activating mutations in
-GMR revealed, among others, an amino acid
exchange V449E within the transmembrane domain, whereas V449Q does not
activate
-GMR (27). Second, the oncogenic activity of the
neu/erb gene product relies on a V664E substitution
localized within the transmembrane domain (36, 37). There is
experimental evidence for this mutation to enhance constitutive
oligomerization of oncogenic neu-V664E in contrast to
c-neu (38, 39). When a panel of neu mutations was
investigated, it turned out that besides V664E only V664Q and, to a
much lower extent, V664D, had transforming capacity, in contrast to
V663E or V665E and four other amino acid substitutions at position 664 (Gly, Lys, His, and Tyr) (36). However, when a mutation analogous to
neu-V664E was introduced into the epidermal growth factor
receptor, activity of the receptor remained fully ligand-dependent (40). In addition, charged amino acids in
the transmembrane region are also believed to be essential for the interaction of natural killer cell inhibitory receptor with the immunoreceptor DAP12 (41).
Constitutive receptor oligomerization is believed to be necessary for
constitutive receptor activation. For example, the transforming R129C
mutation in the EpoR leads to constitutive receptor dimerization (42).
However, the actual situation is more complex, since dimerization of
EpoR may be necessary but not sufficient for receptor activation (10,
43). In contrast to constitutively active receptor mutants, the
/
-GMR described remains fully ligand-dependent.
Structural data of the transmembrane and the membrane-proximal region
are needed to understand the molecular details of receptor interactions determining gain or loss of function of cellular receptors in a
ligand-dependent or -independent manner.
 |
ACKNOWLEDGEMENTS |
We acknowledge Claus Urbanke, Medical School
Hannover, for carrying out predictions of secondary protein structure
and assisting with their interpretation.
 |
FOOTNOTES |
*
This work was supported by Deutsche Forschungsgemeinschaft
Grant Ed 34/2-2 (to M. E.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Medizinische
Hochschule Hannover, Zentrum der Inneren Medizin, Abteilung
Hämatologie und Onkologie, Carl-Neuberg Strasse 1, D-30623
Hannover, Germany. Tel.: 49-511-532-3020; Fax: 49-511-532-3611; E-mail:
Eder.Matthias@MH-Hannover.de.
2
C. Urbanke, personal communication.
3
U. Kalina and M. Eder, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
GM-CSF, granulocyte-macrophage colony-stimulating factor;
GMR, GM-CSF receptor;
IL, interleukin;
EpoR, erythropoietin receptor;
PI-3K, phosphatidylinositol 3-kinase;
hGM-CSF, human GM-CSF;
mIL, murine IL;
PCR, polymerase chain reaction;
RT, reverse transcriptase;
FACS, fluorescence-activated cell sorting. JAK, Janus kinase;
CSR
, CS
receptor
.
 |
REFERENCES |
| 1.
|
Lopez, A. F.,
Williamson, D. J.,
Gamble, J. R.,
Begley, C. G.,
Harlan, J. M.,
Klebanoff, S. J.,
Waltersdorph, A.,
Wong, G.,
Clark, S. C.,
and Vadas, M. A.
(1986)
J. Clin. Invest.
78,
1220-1228
|
| 2.
|
Metcalf, D.
(1989)
Nature
339,
27-30[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Hayashida, K.,
Kitamura, T.,
Gorman, D. M.,
Arai, K.-I.,
Yokota, T.,
and Miyajima, A.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
9655-9659[Abstract/Free Full Text]
|
| 4.
|
Kitamura, T.,
Sato, N.,
Arai, K.,
and Miyajima, A.
(1991)
Cell
66,
1165-1174[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Tavernier, J.,
Devos, R.,
Cornelis, S.,
Tuypens, T.,
Van der Heyden, J.,
Fiers, W.,
and Plaetinck, G.
(1991)
Cell
66,
1175-1184[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Bagley, C. J.,
Woodcock, J. M.,
Stomski, F. C.,
and Lopez, A. F.
(1997)
Blood
89,
1471-1482[Free Full Text]
|
| 7.
|
Bazan, J. F.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
6934-6938[Abstract/Free Full Text]
|
| 8.
|
Schindler, C.,
and Darnell, J. E.
(1995)
Annu. Rev. Biochem.
64,
621-651[Medline]
[Order article via Infotrieve]
|
| 9.
|
Ihle, J. N.
(1995)
Nature
377,
591-594[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Livnah, O.,
Stura, E. A.,
Middleton, S. A.,
Johnson, D. L.,
Jolliffe, L. K.,
and Wilson, I. A.
(1999)
Science
283,
987-990[Abstract/Free Full Text]
|
| 11.
|
Eder, M.,
Ernst, T. J.,
Ganser, A.,
Jubinsky, P. T.,
Inhorn, R.,
Hoelzer, D.,
and Griffin, J. D.
(1994)
J. Biol. Chem.
269,
30173-30180[Abstract/Free Full Text]
|
| 12.
|
Woodcock, J. M.,
McClure, B. J.,
Stomski, F. C.,
Elliott, M. J.,
Bagley, C. J.,
and Lopez, A. F.
(1997)
Blood
90,
3005-3017[Abstract/Free Full Text]
|
| 13.
|
Quelle, F. W.,
Sato, N.,
Witthuhn, B. A.,
Inhorn, R. C.,
Eder, M.,
Miyajima, A.,
Griffin, J. D.,
and Ihle, J. N.
(1994)
Mol. Cell. Biol.
14,
4335-4341[Abstract/Free Full Text]
|
| 14.
|
Witthuhn, B. A.,
Quelle, F. W.,
Silvennoinen, O.,
Yi, T.,
Tang, B.,
Miura, O.,
and Ihle, J. N.
(1993)
Cell
74,
227-236[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Argetsinger, L. S.,
Campbell, G. S.,
Yang, X.,
Witthuhn, B. A.,
Silvennoinen, O.,
Ihle, J. N.,
and Carter-Su, C.
(1993)
Cell
74,
237-244[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Muto, A.,
Watanabe, S.,
Miyajima, A.,
Yokota, T.,
and Arai, K.
(1995)
Biophys. Biochem. Res. Commun.
208,
368-375
|
| 17.
|
Takaki, S.,
Kanazawa, H.,
Shiiba, M.,
and Takatsu, K.
(1994)
Mol. Cell. Biol.
14,
7404-7413[Abstract/Free Full Text]
|
| 18.
|
Weiss, M.,
Yokoyama, C.,
Shikama, Y.,
Naugle, C.,
Druker, B.,
and Sieff, C. A.
(1993)
Blood
82,
3298-3306[Abstract/Free Full Text]
|
| 19.
|
Sakamaki, K.,
Miyajima, I.,
Kitamura, T.,
and Miyajima, A.
(1992)
EMBO J.
11,
3541-3549[Medline]
[Order article via Infotrieve]
|
| 20.
|
Ronco, L. V.,
Doyle, S. E.,
Raines, M.,
Park, L. S.,
and Gasson, J. C.
(1995)
J. Immunol.
154,
3444-3453[Abstract]
|
| 21.
|
Doyle, S. E.,
and Gasson, J. C.
(1998)
Blood
92,
867-876[Abstract/Free Full Text]
|
| 22.
|
Matsuguchi, T.,
Zhao, Y.,
Lilly, M. B.,
and Kraft, A. S.
(1997)
J. Biol. Chem.
272,
17450-17459[Abstract/Free Full Text]
|
| 23.
|
Ding, D. X.,
Rivas, C. I.,
Heaney, M. L.,
Raines, M. A.,
Vera, J. C.,
and Golde, D. W.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
2537-2541[Abstract/Free Full Text]
|
| 24.
|
Chou, P. Y.,
and Fasman, G. D.
(1974)
Biochemistry
13,
211-222[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Kyte, J.,
and Doolittle, R. F.
(1982)
J. Mol. Biol.
157,
105-132[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Okuda, K.,
Smith, L.,
Griffin, J. D.,
and Foster, R.
(1997)
Blood
90,
4759-4766[Abstract/Free Full Text]
|
| 27.
|
Jenkins, B. J.,
D'Andrea, A. D.,
and Gonda, T. J.
(1995)
EMBO J.
14,
4276-4287[Medline]
[Order article via Infotrieve]
|
| 28.
|
Hemmings, B. A.
(1997)
Science
275,
628-630[Free Full Text]
|
| 29.
|
Datta, S. R.,
Dudek, H.,
Tao, X.,
Masters, S.,
Fu, H.,
Gotoh, Y.,
and Greenberg, M. E.
(1997)
Cell
91,
231-241[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Salgia, R.,
Li, J. L.,
Ewaniuk, D. S.,
Pear, W.,
Pisick, E.,
Burky, S. A.,
Ernst, T.,
Sattler, M.,
Chen, L. B.,
and Griffin, J. D.
(1997)
J. Clin. Invest.
100,
46-57[Medline]
[Order article via Infotrieve]
|
| 31.
|
Bhatia, R.,
Wayner, E. A.,
McGlave, P. G.,
and Verfaillie, C. M.
(1994)
J. Clin. Invest.
94,
384-391
|
| 32.
|
Nobes, C. D.,
and Hall, A.
(1995)
Cell
81,
53-62[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Songyang, Z.,
Baltimore, D.,
Cantley, L. C.,
Kaplan, D. R.,
and Franke, T. F.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11345-11350[Abstract/Free Full Text]
|
| 34.
|
Dudek, H.,
Datta, S. R.,
Franke, T. F.,
Birnbaum, M. J.,
Yao, R.,
Cooper, G. M.,
Segal, R. S.,
Kaplan, D. R.,
and Greenberg, M. E.
(1997)
Science
275,
661-665[Abstract/Free Full Text]
|
| 35.
|
Muto, A.,
Watanabe, S.,
Miyajima, A.,
Yokota, T.,
and Arai, K.
(1996)
J. Exp. Med.
183,
1911-1916[Abstract/Free Full Text]
|
| 36.
|
Bargmann, C. I.,
and Weinberg, R. A.
(1988)
EMBO J.
7,
2043-2052[Medline]
[Order article via Infotrieve]
|
| 37.
|
Bargmann, C. I.,
Hung, M. C.,
and Weinberg, R. A.
(1986)
Cell
45,
649-657[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38. |